Analysts Set Expectations for MAIA Biotechnology Q1 Earnings

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA - Free Report) - Analysts at Diamond Equity issued their Q1 2025 earnings estimates for MAIA Biotechnology in a report released on Thursday, November 14th. Diamond Equity analyst H. Diamond anticipates that the company will post earnings of ($0.25) per share for the quarter. The consensus estimate for MAIA Biotechnology's current full-year earnings is ($1.25) per share. Diamond Equity also issued estimates for MAIA Biotechnology's Q2 2025 earnings at ($0.31) EPS, Q3 2025 earnings at ($0.36) EPS, Q4 2025 earnings at ($0.43) EPS and FY2025 earnings at ($1.35) EPS.

MAIA Biotechnology (NYSEAMERICAN:MAIA - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share for the quarter, beating analysts' consensus estimates of ($0.32) by $0.21.

MAIA Biotechnology Stock Performance

NYSEAMERICAN MAIA traded up $0.09 on Monday, hitting $2.35. 152,075 shares of the company traded hands, compared to its average volume of 286,517. MAIA Biotechnology has a 52-week low of $0.82 and a 52-week high of $5.99. The company has a market capitalization of $59.53 million, a PE ratio of -1.79 and a beta of 0.32.

Insider Activity

In other MAIA Biotechnology news, Director Cristian Luput purchased 22,133 shares of the stock in a transaction that occurred on Friday, November 1st. The stock was purchased at an average price of $2.51 per share, with a total value of $55,553.83. Following the acquisition, the director now owns 389,483 shares in the company, valued at approximately $977,602.33. The trade was a 6.03 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 36.98% of the company's stock.

Institutional Investors Weigh In On MAIA Biotechnology

Several hedge funds and other institutional investors have recently modified their holdings of the business. XTX Topco Ltd purchased a new position in shares of MAIA Biotechnology during the third quarter valued at $31,000. Mather Group LLC. lifted its stake in shares of MAIA Biotechnology by 50,150.0% during the 2nd quarter. Mather Group LLC. now owns 12,060 shares of the company's stock worth $41,000 after purchasing an additional 12,036 shares during the last quarter. Ground Swell Capital LLC bought a new stake in shares of MAIA Biotechnology in the 2nd quarter valued at about $56,000. Virtu Financial LLC acquired a new position in shares of MAIA Biotechnology during the first quarter worth $71,000. Finally, Geode Capital Management LLC increased its position in MAIA Biotechnology by 22.9% during the 3rd quarter. Geode Capital Management LLC now owns 192,563 shares of the company's stock valued at $541,000 after buying an additional 35,821 shares in the last quarter. 5.65% of the stock is currently owned by hedge funds and other institutional investors.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.